Key Points
Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence.
Eli Lilly’s stronger GLP-1 growth and consistency support its premium versus Novo’s conditional value story.
Is Novo Nordisk(NYSE: NVO) a bargain or a value trap as it battles Eli Lilly(NYSE: LLY) for GLP‑1 leadership, execution credibility, and premium growth? Watch the video below to see how investors might navigate this high‑stakes rivalry.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
*This video was published on Feb. 24, 2026.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $534,817!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,912!*
Now, it’s worth noting Stock Advisor’s total average return is 964% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 6, 2026.
Andy Cross has no position in any of the stocks mentioned. Loren Horst has positions in Novo Nordisk. Nicholas Sciple has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
